Introduction
India is the highest tuberculosis (TB) burden country in the world. The global incidence of multidrug-resistant TB (MDR-TB) is 630,000 cases. India constitutes one tenth of the global burden with 64,000 cases, presently. [1] Though the conventional drug susceptibility testing (DST) is considered the "Gold standard" for the detection of drug-resistant TB, it is time-consuming taking about 6-8 weeks. [2] Hence, there is need of introduction of rapid diagnostic tools to detect MDR-TB. Cartridge-based nucleic acid amplification test (CBNAAT) is based on real-time amplification and detection of Mycobacterium tuberculosis (MTB), as well as drug sensitivity to rifampicin in a clinical specimen. Line probe assay (LPA) is based on multiplex polymerase chain reaction that is used to detect MTB complex as well as drug sensitivity to rifampicin and isoniazid. In both the tools, rifampicin resistance is detected by the presence of mutations in the 81-bp hotspot region of the rpoB gene. [3] The aim of this study is to report the utility of rapid molecular tools in diagnosis of drug resistance TB. January-March 2016 www.ijmm.org MTB/RIF kit (Cepheid AB, Sweden) as per manufacturer's specification. [5] Automated results generated by CBNAAT and were communicated online.
A total of 360 AFB positive samples were processed by NALC-NaOH decontamination method. DNA was extracted from decontaminated samples using Genolyse ® kit (Hain Lifescience GmbH, Nehren, Germany) as per manufacturer's instructions. [6, 7] The extracted DNA was processed by the LPA using GenoType ® MTBDRplus (Hain Lifescience GmbH, Nehren, Germany) for detection of MTB complex and rifampicin and isoniazid resistance. A positive MTB control (TUB) band indicated the presence of members of the MTB complex in the sputum sample. [8] Samples with no TUB band by LPA (n = 16) were cultured on p-nitro benzoic acid (PNB) containing media and plain Lowenstein-Jensen (LJ) media for further confirmation as per Revised National Tuberculosis Control Program (RNTCP) guidelines. [9] DNA was extracted from colonies of those samples that showed growth of AFB and LPA were carried out on the extracted DNA as above.
Results
A total of 682/1253 (54.4%) patients were resistant and 449/1253 (35.8%) were sensitive for rifampicin. In a total of 112/1253 (8.9%) cases MTB was not detected; two cases were diagnosed as error and eight showed indeterminate for rifampicin by CBNAAT and LPA [ Table 1 ]. Specimens of 106 patients that were negative for MTB (by CBNAAT), showed error and indeterminate by CBNAAT and LPA were requested to send their samples to certified culture DST laboratory for phenotypic DST as per the program recommendation. Out of 682,208 cases were resistant by LPA whereas 474 cases were rifampicin-resistant by CBNAAT. Rifampicin resistance has seen to be (57.7%) in LPA and (53.0%) in CBNAAT. Of total 360 diagnosed cases by LPA 129 were sensitive and seven patients showed indeterminate for rifampicin. A total of 16/360 (4.4%) showed negative for MTB by LPA. Out of 16 cultures, thirteen cultures turned positive (8 cultures showed positive on plain and PNB, 5 were positive on plain only), two cultures were negative and one was contaminated. On further DNA extraction and LPA of culture positive samples, all showed negative for MTB.
Discussion
Recently, significant progress has been made in our understanding for the molecular basis of MTB drug resistance. World Health Organisation (WHO) endorsed the use of molecular-based CBNAAT and LPA for screening of MDR-TB, [5, 7] following which these two assays are being used routinely in different countries. [3, 5, 7] We are providing a diagnosis of drug-resistant TB to MDR suspected patients under RNTCP. We found 54.4% of drug resistance to rifampicin which is considered as a surrogate marker for MDR in previously treated patients. This is higher than national observation of 12-17% in MDR suspects. [9] The reason could be selection bias of the patients; as nine linked districts were in Criteria A and one district in Criteria B for the MDR testing. The result could be nearer to national observation when we test in Criteria C for all the linked districts. The high level of rifampicin resistance could also be due to non-availability of rapid diagnostic techniques as a result of which the patients did not have access, and there was a large pool of undiagnosed cases. Our results are correlated with Singhal et al., who reported 55.2% of MDR [10] and Raizada et al. [11] have also found 51% rifampicin-resistant. However, Kumar et al. [12] and Sharma et al. [13] reported 25.8% and 22% of MDR, respectively. A total of 8.9% were negative for MTB detected by both the techniques. This may be due to: (1) Most of them may be having a bacillary load lower than the detection limit of CBNAAT. (2) Few of them could be truly negative for MTB and suspected of non-TB mycobacterium (NTM). Two smear positive turned out culture negative, possibly due to the presence of dead bacilli in sputum samples. Out of the 16 samples which did not give TUB band, 13 were able to grow on LJ medium. However, none of these turned out to be MTB, which indicates that negative TUB band could give an indication of the isolate being NTM.
Diagnosis of drug resistance in TB by established gold standard method (solid culture and DST), takes 8-16 weeks, whereas molecular methods could diagnose rifampicin resistance in 2-72 h. Consequently, early management of these patients has a potential of rendering them noninfectious and preventing transmission of MDR strains in the community. This data can also help us in monitoring the MDR level in this region of Uttar Pradesh. 
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